Apogee Therapeutics, Inc.

APGE Nasdaq CIK: 0001974640

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
Business Address 221 CRESCENT ST., WALTHAM, MA, 02453
Mailing Address 221 CRESCENT ST., WALTHAM, MA, 02453
Phone 650-394-5230
Fiscal Year End 1231
EIN 934958665

Financial Overview

FY2025

$-3.30
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 27, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 27, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
424B5 Prospectus supplement March 25, 2026 View on SEC
424B5 Prospectus supplement March 23, 2026 View on SEC
8-K Current report of material events March 23, 2026 View on SEC
4 Insider stock transaction report March 13, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 6, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC

Annual Reports

10-K March 2, 2026
  • Successful Initial Public Offering (IPO) in July 2023, which raised substantial capital and listed shares on The Nasdaq Global Market under APGE.
  • Lead program APG990 is currently in Phase 2 clinical trials for Atopic Dermatitis and Asthma, with initial data expected in late 2024 and early 2025.
View Analysis

Insider Trading

STRONG SELL 4 insiders 43 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.